Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
06
09
2019
accepted:
13
05
2020
pubmed:
1
7
2020
medline:
5
11
2020
entrez:
1
7
2020
Statut:
ppublish
Résumé
A burgeoning epidemic of drug-resistant tuberculosis (TB) threatens to derail global control efforts. Although the mechanisms remain poorly clarified, drug-resistant strains are widely believed to be less infectious than drug-susceptible strains. Consequently, we hypothesized that lower proportions of patients with drug-resistant TB would have culturable Mycobacterium tuberculosis from respirable, cough-generated aerosols compared to patients with drug-susceptible TB, and that multiple factors, including mycobacterial genomic variation, would predict culturable cough aerosol production. We enumerated the colony forming units in aerosols (≤10 µm) from 452 patients with TB (227 with drug resistance), compared clinical characteristics, and performed mycobacterial whole-genome sequencing, dormancy phenotyping and drug-susceptibility analyses on M. tuberculosis from sputum. After considering treatment duration, we found that almost half of the patients with drug-resistant TB were cough aerosol culture-positive. Surprisingly, neither mycobacterial genomic variants, lineage, nor dormancy status predicted cough aerosol culture positivity. However, mycobacterial sputum bacillary load and clinical characteristics, including a lower symptom score and stronger cough, were strongly predictive, thereby supporting targeted transmission-limiting interventions. Effective treatment largely abrogated cough aerosol culture positivity; however, this was not always rapid. These data question current paradigms, inform public health strategies and suggest the need to redirect TB transmission-associated research efforts toward host-pathogen interactions.
Identifiants
pubmed: 32601338
doi: 10.1038/s41591-020-0940-2
pii: 10.1038/s41591-020-0940-2
pmc: PMC8353872
mid: NIHMS1726937
doi:
Substances chimiques
Aerosols
0
Antitubercular Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1435-1443Subventions
Organisme : Wellcome Trust
ID : 099854/Z/12/Z
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI104817
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : MR/S027777/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S03563X/1
Pays : United Kingdom
Références
Sci Rep. 2018 Mar 29;8(1):5382
pubmed: 29599463
Bull Int Union Tuberc. 1975;50(1):107-21
pubmed: 1218286
Mol Microbiol. 2014 Mar;91(6):1106-19
pubmed: 24417450
PLoS Pathog. 2006 Jun;2(6):e61
pubmed: 16789833
Lancet Respir Med. 2017 Apr;5(4):269-281
pubmed: 28109869
Clin Infect Dis. 2008 Nov 1;47(9):1135-42
pubmed: 18823268
Infect Genet Evol. 2012 Jun;12(4):755-66
pubmed: 22365971
Am J Respir Crit Care Med. 2018 Nov 1;198(9):1208-1219
pubmed: 29877726
Lancet Respir Med. 2017 Mar 15;:
pubmed: 28344011
Int J Tuberc Lung Dis. 2014 Sep;18(9):1019-25
pubmed: 25189547
Lancet Infect Dis. 2013 Feb;13(2):137-46
pubmed: 23158499
Int J Tuberc Lung Dis. 2016 Mar;20(3):329-34
pubmed: 27046713
Antimicrob Agents Chemother. 2014;58(1):11-8
pubmed: 24100497
J Clin Microbiol. 2015 Nov;53(11):3633-5
pubmed: 26292310
Microbiology (Reading). 2002 Oct;148(Pt 10):2951-8
pubmed: 12368428
Clin Infect Dis. 2015 Jul 1;61(1):1-8
pubmed: 25778753
Clin Infect Dis. 2007 May 15;44(10):1349-57
pubmed: 17443474
Lancet Infect Dis. 2017 Apr;17(4):441-450
pubmed: 28063795
Nat Genet. 2011 Dec 18;44(1):106-10
pubmed: 22179134
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Am J Respir Crit Care Med. 2013 May 1;187(9):1007-15
pubmed: 23306539
Bioinformatics. 2012 Nov 15;28(22):2991-3
pubmed: 23014632
PLoS One. 2013;8(3):e59414
pubmed: 23527189
BMC Infect Dis. 2019 Mar 12;19(1):244
pubmed: 30866840
Nat Genet. 2014 Mar;46(3):279-86
pubmed: 24464101
Epidemiology. 2013 May;24(3):395-400
pubmed: 23446314
Nature. 2005 Nov 17;438(7066):355-9
pubmed: 16292310
Lancet. 2014 Apr 5;383(9924):1230-9
pubmed: 24439237
Am J Respir Crit Care Med. 2004 Mar 1;169(5):604-9
pubmed: 14656754
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):338-42
pubmed: 8990210
Scand J Infect Dis. 2008;40(2):111-20
pubmed: 17852907
Tubercle. 1976 Dec;57(4):275-99
pubmed: 827837
Lancet Infect Dis. 2015 Oct;15(10):1193-1202
pubmed: 26116186
Int J Infect Dis. 2019 Feb;79:65-71
pubmed: 30395979
Drugs. 2014 Jul;74(10):1063-72
pubmed: 24962424
Am J Respir Crit Care Med. 2016 Dec 15;194(12):1532-1540
pubmed: 27387272
Am J Respir Crit Care Med. 2012 Sep 1;186(5):450-7
pubmed: 22798319
Lancet Infect Dis. 2016 Feb;16(2):227-38
pubmed: 26867464
Am Rev Respir Dis. 1962 Apr;85:511-25
pubmed: 14492300
Tuberculosis (Edinb). 2011 Jul;91(4):329-38
pubmed: 21478054
J Clin Microbiol. 2006 Jan;44(1):254-6
pubmed: 16390984
Eur Respir J. 2017 Oct 26;50(4):
pubmed: 29074544
Antimicrob Agents Chemother. 2013 Feb;57(2):827-32
pubmed: 23208709
Nat Genet. 2013 Oct;45(10):1183-9
pubmed: 23995135
Am Rev Respir Dis. 1960 Sep;82:358-69
pubmed: 13835667
Clin Infect Dis. 2010 Aug 15;51(4):371-8
pubmed: 20624064
Infect Immun. 2006 Jul;74(7):3790-803
pubmed: 16790751
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Int J Tuberc Lung Dis. 2010 Jan;14(1):119-21
pubmed: 20003705
Genome Med. 2015 May 27;7(1):51
pubmed: 26019726
Clin Infect Dis. 2016 Jul 1;63(1):10-20
pubmed: 27025837